Hepatitis: Ahn S

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 2 Articles   Help
A digest of articles written 1999 and later, on the topic "Hepatitis," originating from Planet Earth —» Ahn S.  Display:  All Citations ·  All Abstracts
1 Review Innovative vaccine production technologies: the evolution and value of vaccine production technologies. 2009

Bae K, Choi J, Jang Y, Ahn S, Hur B. · Vaccine Research Institute, CrucellBerna Biotech Korea, Yongin, 449-903, Korea. · Arch Pharm Res. · Pubmed #19407962 No free full text.

Abstract: This review paper provides an overview of innovative technologies designed to produce bacterial, viral, recombinant subunit, and polysaccharide vaccines, as well as combination vaccines. Advances in this field are illustrated by vaccines against DTP (diphtheria-tetanus-pertussis), influenza, hepatitis B (HepB) and typhoid fever. In addition, technological trends regarding antigens, adjuvants, and preservatives in vaccines are discussed. The progress achieved in vaccine production technologies is especially important for improving the protection of vulnerable populations against infectious diseases. These at-risk groups include infants, the elderly and immunocompromized individuals, as well as people living in developing countries or emerging economies.

2 Article A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. 2004

Choi JR, Cho DG, Roh KY, Hwang JT, Ahn S, Jang HS, Cho WY, Kim KW, Cho YG, Kim J, Kim YZ. · LG Life Sciences Ltd., R & D Park, 104-1 Moongi-dong, Yusung-gu, Daejeon 305-380, Korea. · J Med Chem. · Pubmed #15139764 No free full text.

Abstract: 9-[1-(Phosphonomethoxycyclopropyl)methyl]guanine (PMCG, 1), representative of a novel class of phosphonate nucleosides, blocks HBV replication with excellent potency (EC(50) = 0.5 microM) in a primary culture of HepG2 2.2.15 cells. It exhibits no significant cytotoxicity in several human cell lines up to 1.0 mM. It does not inhibit replication of human immunodeficiency virus (HIV-1) or herpes simplex virus (HSV-1) at 30 microM. Many purine base analogues of 1 also exhibit inhibitory activity against HBV, but at 30 microM, pyrimidine analogues do not. 1 is 4 times more potent than 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA), which was used as a positive control (EC(50) = 2.0 microM). The characteristic cyclopropyl moiety at the 2'-position of 1 was prepared by titanium-mediated Kulinkovich cyclopropanation. 1 was modified to give the orally available drug candidate, PMCDG Dipivoxil (2). Compound 2 exhibited excellent efficacy when administered at 5 mg per kg per day in a study with woodchucks infected with woodchuck hepatitis B virus (WHBV). Drug candidate 2 has successfully completed phase I clinical trials and is currently undergoing phase II clinical studies for evaluation of efficacy.